What people ask
Searched every month
- can you stop wegovy cold turkey480
- stopping wegovy480
- stopping zepbound480
- stopping tirzepatide390
US Google searches a month, 12-month average to November 2026 (Google Ads Keyword Planner).
What the research says
The numbers, on average
- Nonerandomized taper trials found in Alma’s review of the research, November 2026
- 16.6%below starting weight at week 112 after stepping down to 5 mg tirzepatide, on average (378 people)1
- 30 of 34stayed on spaced dosing without going back to weekly, in a case series with no comparison group2
- Full dose
- −21.9%
- Stepped down to 5 mg
- −16.6%
- Placebo
- −9.9%
Stopping all at once
STEP 4 and SURMOUNT-4 switched people straight to placebo. Weight came back in both.4
Stepping down the dose
SURMOUNT-MAINTAIN moved 378 people to full dose, 5 mg or placebo. At week 112 they were 21.9%, 16.6% and 9.9% below their start, on average.1
Spacing out doses
30 adults moved to dosing about every other week for 36 weeks on average. Weight went from 74.1 to 72.4 kg on average. 4 of 34 went back to weekly.2
What it means for meals
Keep meals steady while doses change
Steady protein
Keep a palm-sized portion of protein at each meal, whatever the dose is doing.
Fiber at breakfast
Oats, berries and seeds make an easy high-fiber start.
Notice hunger changes
Logging meals shows whether portions are creeping up as the medicine wears off.
Alma logs a meal from a photo, voice or text in about 10 seconds and shows protein and fiber for each meal.
Questions people ask
Can I taper myself?
No. Any change to the dose or how often you take it should come from your prescriber.
What do the labels say about missed doses?
The Wegovy label says a prescriber may restart with dose escalation if 2 or more doses are missed. The Zepbound label says to take a missed dose within 4 days.
Is microdosing the same as tapering?
Not exactly, and no trial has tested microdosing. The maintenance dose part of this series covers what is known.
Sources
- SURMOUNT-MAINTAIN 2026. Full-dose vs lower-dose tirzepatide vs placebo for weight maintenance. PubMed.
- Wong et al. 2026. Reduced-frequency GLP-1 therapy after a weight plateau: a case series. Obesity.
- Rubino et al. 2021. Continued vs withdrawn semaglutide for weight maintenance: the STEP 4 trial. JAMA.
- Aronne et al. 2024. Continued tirzepatide vs placebo for weight maintenance: the SURMOUNT-4 trial. JAMA.
- FDA. Wegovy (semaglutide) prescribing information, 2025.
- FDA. Zepbound (tirzepatide) prescribing information, 2025.
US Google searches a month, 12-month average to November 2026 (Google Ads Keyword Planner). Editorial standards
Alma does not give medical advice. Starting, stopping or changing a GLP-1 dose is a decision for your prescriber.
